This trial aims to test how two different formulations of BI 690517 are taken up by the body and how probenecid influences the amount of BI 690517 in the blood.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
AUC0-tz (area under the concentration-time curve of BI 690517 in plasma over the time interval from 0 to the last quantifiable data point)
For the relative bioavailability of BI 690517.
Time frame: Up to day 3.
Cmax (maximum measured concentration of BI 690517 in plasma)
For the relative bioavailability of BI 690517.
Time frame: Up to day 3.
AUC0-∞ (area under the concentration-time curve of BI 690517 in plasma over the time interval from 0 extrapolated to infinity)
For the drug interaction of BI 690517 with probenecid.
Time frame: Up to day 3.
Cmax (maximum measured concentration of BI 690517 in plasma)
For the drug interaction of BI 690517 with probenecid.
Time frame: Up to day 3.
AUC0-∞ (area under the concentration-time curve of BI 690517 in plasma over the time interval from 0 extrapolated to infinity)
For the relative bioavailability of BI 690517.
Time frame: Up to day 3.
AUC0-tz (area under the concentration-time curve of BI 690517 in plasma over the time interval from 0 to the last quantifiable data point)
For the drug interaction of BI 690517 with probenecid.
Time frame: Up to day 3.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.